Sign In
Buy KVUE
$19.24
-0.0700 (-0.363%)
At Close: Jul 31, 2026
Earnings Preview: Kenvue (KVUE) Q3 Earnings Expected to Decline
11:06am, Thursday, 30'th Oct 2025
Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kenvue: Temporary Headwinds Don't Derail Its Consumer Health Dominance And 5.5% Dividend Yield
02:30pm, Wednesday, 29'th Oct 2025
Kenvue offers a defensive, dividend-rich investment opportunity after a 34% stock decline, trading at a 10% discount to peers. KVUE's 5.5% dividend yield and strong operating margins make it attractiv
US health chief says not enough data to show Tylenol causes autism, but still advises caution
02:08pm, Wednesday, 29'th Oct 2025
U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday said there is not enough evidence to show that Kenvue's pain medicine Tylenol definitively causes autism, but said that it should still be used
Kenvue Declares Quarterly Cash Dividend
06:45am, Wednesday, 29'th Oct 2025
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is pa
Analyzing Kenvue (NYSE:KVUE) and PURPLE INNOVATION (NASDAQ:PRPL)
04:32am, Wednesday, 29'th Oct 2025
Kenvue (NYSE: KVUE - Get Free Report) and PURPLE INNOVATION (NASDAQ: PRPL - Get Free Report) are both consumer staples companies, but which is the better investment? We will compare the two businesses
Embattled Tylenol Maker Kenvue Hires New Marketing Chief
03:23pm, Tuesday, 28'th Oct 2025
The company plans to name snack food executive Jon Halvorson as it faces a crisis over concerns of links between Tylenol and autism.
Texas sues J&J and Kenvue, claiming they hid Tylenol's autism risks
09:13am, Tuesday, 28'th Oct 2025
The makers of Tylenol, Johnson & Johnson and Kenvue , were sued on Tuesday by Texas Attorney General Ken Paxton, who accused them of knowingly hiding the drug's links to autism and attention deficit h
Texas sued Tylenol maker Kenvue, alleging it deceived pregnant women about risks associated with autism
08:39am, Tuesday, 28'th Oct 2025
The suit alleges that the Tylenol maker engaged in deceptive marketing by advertising the product as safe to use while pregnant.
Renaissance Capital Bets Big on Tylenol and Kenvue (KVUE) By Purchasing Over 351,000 Shares
11:46am, Monday, 27'th Oct 2025
Renaissance Capital bought 351,259 additional shares of Kenvue; estimated trade value of approximately $7.17 million, based on the average price in Q3 2025 This trade represented 4.02% of Renaissance
Time To Buy The Dip In Kenvue Stock?
10:25am, Monday, 27'th Oct 2025
Kenvue (NYSE:KVUE), the consumer healthcare spin-off from Johnson & Johnson, has experienced a significant decline in its stock price in recent months. The shares are currently priced around $15, whic
Kenvue to Announce Third Quarter 2025 Results on November 6, 2025
06:45am, Monday, 27'th Oct 2025
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its third quarter 2025 financial results before the market opens on November 6, 2025. The company will host a conference call and
3 Healthcare Stocks Paying the Highest Dividends of 2025
04:30am, Monday, 27'th Oct 2025
Kenvue was spun off from Johnson & Johnson in mid-2023, and its life is starting out a little rough. Pfizer is working through typical drug industry issues, but there's a notable dividend risk to cons
Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever.
04:00am, Sunday, 26'th Oct 2025
Kenvue owns Johnson & Johnson's former over-the-counter brands. Medtronic has a diversified medical-device portfolio and is closing in on "Dividend King" status.
US IPO Weekly Recap: 5 Small IPOs Debut, As Government Shutdown Drags On
05:43am, Saturday, 25'th Oct 2025
Five small IPOs debuted and four SPACs listed this week as the government shutdown continues to complicate listings. Two sizable IPOs are scheduled for the week ahead, both of which launched after the
Starboard Value CEO: We're thrilled to own Kenvue at this valuation
11:07am, Tuesday, 21'st Oct 2025
Starboard Value CEO Jeff Smith joins CNBC's David Faber from 13D Monitor's Active-Passive Investor Summit.
